A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
Open accessThe DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Abstract
Aberrant Wnt signaling activation is frequently observed in many cancers. The mutation acquisition of Wnt signaling leads to tumorigenesis, whereas the inhibition of Wnt signaling robustly suppresses tumor development in various in vivo models. Based on the excellent preclinical effect of targeting Wnt signaling, over the past 40 years, numerous Wnt-targeted therapies have been investigated for cancer treatment. However, Wnt signaling-targeting drugs are still not clinically available. A major obstacle to Wnt targeting is the concomitant side effects during treatment due to the pleiotropic role of Wnt signaling in development, tissue homeostasis, and stem cells. Additionally, the complexity of the Wnt signaling cascades across different cancer contexts hinders the development of optimized targeted therapies. Although the therapeutic targeting of Wnt signaling remains challenging, alternative strategies have been continuously developed alongside technological advances. In this review, we give an overview of current Wnt targeting strategies and discuss recent promising trials that have the potential to be clinically realized based on their mechanism of action. Furthermore, we highlight new waves of Wnt targeting that combine recently developed technologies such as PROTAC/molecular glue, antibody–drug conjugates (ADC), and anti-sense oligonucleotides (ASO), which may provide us with new opportunities to target ‘undruggable’ Wnt signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple agents targeting both canonical and the β-catenin-independent non-canonical Wnt signaling including v-ATPase inhibitors and anti-RSPO antibody are undergoing clinical trials in CRC and other malignancies [119,120].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [119]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499 · cited 2×
“For example, genetic mutations of Wnt signaling in colorectal cancer (CRC) are observed in more than 90% of patients and are well-known cancer-driving alterations [25,26].”
BackgroundMutations affecting segment number and polarity in Drosophila
Nüsslein-Volhard, C., & Wieschaus, E. (1980) · Nature · doi:10.1038/287795a0 · Cited by 4,370
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Crypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Huang, S.-M. A., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009) · Nature · doi:10.1038/nature08356 · Cited by 2,037
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Nusse, R., & Varmus, H. E. (1982) · Cell · doi:10.1016/0092-8674(82)90409-3 · Cited by 1,863 · cited 1×
“Concurrently, Int-1, a mammalian wingless homolog, was identified as a driver gene for malignancy when its transcriptional activation was induced by the murine mammary tumor virus [2].”
BackgroundGarzon, R., Calin, G. A., & Croce, C. M. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.59.053006.104707 · Cited by 1,770
Cited by
Current advances and development strategies of orally bioavailable PROTACs
Zeng, S., Ye, Y., Xia, H., Min, J., Xu, J., Wang, Z., Pan, Y., Zhou, X., & Huang, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115793 · Cited by 92
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Additionally, recently developed technologies are currently being explored to inhibit Wnt signaling, such as proteolysis-targeting chimeras and molecular glue degraders, antibody–drug conjugates, and antisense oligonucleotides [195].”
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Multiple agents targeting both canonical and the β -catenin-independent non-canonical Wnt signaling including v-ATPase inhibitors and anti-RSPO antibody are undergoing clinical trials in CRC and other malignancies [119,120].”
BackgroundLi, C., Furth, E. E., Rustgi, A. K., & Klein, P. S. (2023) · Cells · doi:10.3390/cells12182256 · Cited by 33
Structural and Functional Insights into Dishevelled-Mediated Wnt Signaling
Wang, L., Zhu, R., Wen, Z., Fan, H., Norwood-Jackson, T., Jathan, D., & Lee, H. (2024) · Cells · doi:10.3390/cells13221870 · Cited by 25
Altered lipid metabolism in APC-driven colorectal cancer: the potential for therapeutic intervention
Kelson, C. O., & Zaytseva, Y. Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1343061 · Cited by 22
“Multiple strategies that target Wnt signaling have been developed, from small molecules to blocking antibodies, and peptide agonists and antagonists (96).”
BackgroundTargeted Treatment against Cancer Stem Cells in Colorectal Cancer
Martínez-Pérez, J., Torrado, C., Domínguez-Cejudo, M. A., & Valladares-Ayerbes, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116220 · Cited by 18
“In preclinical models, it has been observed that the overexpression of ABCB1 and ABCG2 in CRC cells, as well as aberrant regulation of WNT/ β -catenin and active glycogen synthase kinase 3-beta (GSK3 β ) signaling, may lead to resistance to gedatolisib [28,74].”
BackgroundMolecular glue degrader for tumor treatment
Hu, Y., Yan, Y., Wang, J., Hou, J., & Lin, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1512666 · Cited by 19
Gajos-Michniewicz, A., & Czyż, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312804 · Cited by 16
“Therefore, novel therapeutic targets are needed, and modulating WNT/ β -catenin signaling is one of the strategies [25].”
The role of YAP/TAZ mechanosignaling in trabecular meshwork and Schlemm’s canal cell dysfunction
Ghosh, R., & Herberg, S. (2024) · Vision Research · doi:10.1016/j.visres.2024.108477 · Cited by 15
Belling the “cat”: Wnt/β-catenin signaling and its significance in future cancer therapies
Goyal, A., Murkute, S. L., Bhowmik, S., Prasad, C. P., & Mohapatra, P. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189195 · Cited by 19
Al‐Hamaly, M. A., Cox, A. H., Haney, M. G., Zhang, W., Arvin, E. C., Sampathi, S., Wimsett, M., Liu, C., & Blackburn, J. S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116013 · Cited by 13
“Furthermore, the multifaceted cross-talk between Wnt signaling and other crucial pathways necessitates a thorough understanding of potential off-target effects [22,23].”
BackgroundBörding, T., Janik, T., Bischoff, P., Morkel, M., Sers, C., & Horst, D. A. (2024) · Oncogene · doi:10.1038/s41388-024-03200-3 · Cited by 13
“Survival status and time since the last follow-up were plotted against GPA33-levels using Prism (GraphPad).”
Lenz, H., Argilés, G., de Jonge, M. J. A., Yaeger, R. D., Doi, T., El-Khoueiry, A. B., Eskens, F. A. L. M., Kuboki, Y., Bertulis, J., Nazabadioko, S., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103729 · Cited by 12
Infectious Agents Induce Wnt/β-Catenin Pathway Deregulation in Primary Liver Cancers
Catalano, T., Selvaggi, F., Esposito, D. L., Cotellese, R., & Aceto, G. M. (2023) · Microorganisms · doi:10.3390/microorganisms11071632 · Cited by 11
Bu, T., Li, L., & Tian, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1269233 · Cited by 11
“For example, researchers have developed and evaluated the efficacy of Protac/molecular glue, antibody-drug conjugates, and antisense oligonucleotides in inhibiting the Wnt signaling pathway in preclinical models and clinical trials (Park and Kim, 2023).”
MethodWise, D. R., Pachynski, R. K., Denmeade, S. R., Aggarwal, R. R., Deng, J., Febles, V. A., Balar, A. V., Economides, M. P., Loomis, C. A., Selvaraj, S., et al. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00798-z · Cited by 11
Shi, R., Cao, Z. A., Li, J., Ji, R., & Guo, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1633699 · Cited by 10
“These challenges stem from issues related to off-target toxicity, inadequate bioavailability, and the absence of predictive biomarkers (83, 84).”
Canonical WNT/β-catenin signaling upregulates aerobic glycolysis in diverse cancer types
Rathee, M., Umar, S. M., Dev, A. J. R., Kashyap, A., Mathur, S. R., Gogia, A., Mohapatra, P., & Prasad, C. P. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09694-0 · Cited by 12
Targeting the ubiquitin–proteasome system and drug therapy in colorectal cancer
Su, R., Shao, Y., Wang, Q., Liu, D., Wang, Y., Kong, D., & Qiu, Y. (2025) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaf027 · Cited by 10
“Based on the different stages of Wnt signal transduction, current therapeutic strategies fall into four categories: targeting Wnt ligands, targeting Wnt receptors, targeting destruction complexes, and targeting β -catenin/transcription factors (Park and Kim, 2023 ).”
Emerging therapeutic strategies for Wnt-dependent colon cancer targeting macropinocytosis
Tejeda‐Muñoz, N., Binder, G., & Mei, K. (2024) · Cells and Development · doi:10.1016/j.cdev.2024.203974 · Cited by 9
Schwarzmueller, L., Adam, R., Moreno, L. F., Nijman, L. E., Logiantara, A., Eleonora, S., Bril, O., Vromans, S. P. J. M., de Groot, N. E., Giugliano, F. P., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332752 · Cited by 8
“11 However, downstream activation of Wnt/ β -catenin signalling pathway in CRC hinders the therapeutic benefits of blocking extracellular or membrane-bound targets with monoclonal”
Saliu, T. P., Seneviratne, N. N., Faizan, M., Rajagopalan, U., Perera, D. C., Adhikari, A., Senathilake, K. S., Galhena, P., Tennekoon, K. H., & Samarakoon, S. R. (2024) · In Silico Pharmacology · doi:10.1007/s40203-024-00199-z · Cited by 8
WNT5A is a putative epi‐driver of prostate cancer metastasis to the bone
Wilkinson, E. J., Raspin, K., Malley, R. C., Donovan, S., Nott, L. M., Holloway, A. F., & Dickinson, J. L. (2024) · Cancer Medicine · doi:10.1002/cam4.70122 · Cited by 7
“49 WNT5A inhibitors have been shown to effectively suppress melanoma cell invasion in vitro by blocking WNT5A signalling, 50,51 and have been identified as potential therapeutic options for ovarian cancer, 52 however, validation of their clinical utility in vivo is urgently required.”
BackgroundTCF/LEF-mediated transcriptional regulation in the canonical Wnt pathway
Takano, C., & Higuchi, Y. (2025) · Current Molecular Pharmacology · doi:10.1016/j.cmp.2025.09.004 · Cited by 6
Targeting β-catenin: PROTACs and precision degraders for Wnt-driven cancers
Trapani, J. B., Caroland, K. P., Ahmed, Y. F., Robbins, D. J., Weiss, V. L., & Lee, E. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1777843 · Cited by 6
Dayal, N., Chaudhuri, R., Yeboah, K. S., Brauer, N. R., & Sintim, H. O. (2024) · Pharmaceuticals · doi:10.3390/ph17121660 · Cited by 6
Wnt signaling and the tumor microenvironment: implications for cancer progression and therapeutics
Ragupathi, A. B. M., Dang, C. V., & Zabransky, D. J. (2026) · Oncogene · doi:10.1038/s41388-026-03731-x · Cited by 7
Chen, C., Chen, C., Huang, Y., Huang, P.-S., Chi, H., Chuang, H., Lin, M., Huang, T.-H., Hsu, J., & Chen, C. (2023) · Chemotherapy · doi:10.1159/000533767 · Cited by 5
“However, no clinical trial targeting sFRP4 has been conducted at present, while numerous trials of Wnt/ β - catenin targeting therapies are ongoing [44].”
Wnt-Regulated Therapeutics for Blood-Brain Barrier Modulation and Cancer Therapy
An, P., Tong, Y., Mu, R., & Han, L. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00537 · Cited by 4
Towards directed therapy for fusion-positive rhabdomyosarcoma
Turco, G. M., Oberoi, S., Ladle, B. H., Raavi, Wagner, L. M., Koehler, A. N., & Linardic, C. M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108931 · Cited by 4
Tur, R., Abad, M., Filipovich, E., Rivas, M. B., González, M. R., Montero, J. C., & Sayagués, J. M. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i11.112838 · Cited by 5
“However, despite abundant evidence that hyperactivation of the Wnt pathway drives CRC and that therapies targeting this pathway have been effective in preclinical models of CRC, targeted Wnt therapies have not progressed in clinical settings[20].”
Zhao, N., You, W., Zheng, X., Yan, J., Wang, P., Yao, Y., He, W., & Liu, T. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102136 · Cited by 4
“Conversely, agents targeting the Wnt/ β -catenin pathway have focused predominantly on upstream PORCN inhibitors, such as WNT974 and CGX1321, which have shown potential in suppressing tumor stemness, metastasis, and drug resistance [35,43].”
Diagnosis and therapeutic targeting of quiescent cancer cells: road to conquer cancer recurrence
Kim, M. J. (2025) · BMB Reports · doi:10.5483/bmbrep.2025-0007 · Cited by 3
Self-citationHumtsoe, J. O., Keam, B., Kim, H.-S., Jones, L., Leonard, B. C., Pothukuchi, A., Honjo, S., van Zante, A., Lee, S., & Ha, P. K. (2025) · Head & Neck · doi:10.1002/hed.28249 · Cited by 2
“A significant drawback in developing Wnt–β-catenin targeting drugs has been undesired off-target effects and the complexities in signaling regulation due to the heterogeneity of the mechanisms of dysregulation within different cancer types [19, 51].”
Clonal evolution and molecular mechanisms of ovarian cancer: a comprehensive review
Nagasaka, K. (2024) · Academia oncology. · doi:10.20935/acadonco7484 · Cited by 2
Wnt signal pathways: new mechanistic approaches and clinical horizons in cancer therapy
Hassan, H. A., & Abdel-Sater, K. A. (2025) · Medical Oncology · doi:10.1007/s12032-025-02868-1 · Cited by 1
“A few reports of clinical trials of Wnt ligand and FZD inhibitory monoclonal antibody drugs [47].”
Discovery of a dual-target CRBN-mediated degrader for IKZF1/3 and GSPT1 proteins
Tang, C., Li, Z., Lu, R., Yu, G., Gu, Y., & Yao, X. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109367 · Cited by 1
Williams, C. M., Calderon, J. H., DiBlasi, V. R., Liu, L. J., Nuwayhid, S. J., Cevasco, H., Wang, W., Soni, R., Adler, C., D’Ambrosio, D. W., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-40894-9 · Cited by 1
“Currently, there are no WNT-targeted therapies approved 41 .”
Evans, T. R. J., Cook, N., El-Khoueiry, A. B., Pinato, D. J., Tran, N. H., Hsiehchen, D., Mena, E., Meyer, T., Wu, J., Pathak, S. M., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03488-w · Cited by 1
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
Bilotta, M., Gargano, A., Rocca, R., Maggisano, V., Bulotta, S., & Alcaro, S. (2026) · Pharmaceuticals · doi:10.3390/ph19081310 · Cited by 1
“Among its diverse functions, the modulation of the Wnt/ β -catenin pathway is particularly relevant in cancer biology [7,8].”
Scavuzzo, A., Poncina, M., Lamolinara, A., Sarcinella, A., Jahanbin, M., Filippone, M. G., Bottoni, L., Tucci, F. A., Vinik, Y., Lev, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.14.744806 · Cited by 1
Huang, Z., Zhang, T., Pan, J., Zhang, G., Jiang, L., Jiang, H., Wan, P., Peng, Y. B., Zou, W., Liu, Q., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70672
“Several studies [17–19] have demonstrated the aberrant activation of the Wnt signaling pathway in NMIBC.”
Sevim, O., Wagstaff, M., Ling, R. E., Goff, A., Palmer, D. A., Park, H., Hills, K., Castellano, L., Newbury, S. F., Roy, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.25.698240
“Previous approaches to targeting Wnt/ β -catenin signalling have shown promise with a number of agents reaching Phase I or II clinical trials predominantly in solid cancers, 11 as exemplified by WNT974 (PORCN inhibitor preventing Wnt ligand palmitoylation and secretion).”
Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications
Wen, J., Yu, J., Wen, W., & Jiang, B. (2026) · MedComm – Oncology · doi:10.1002/mog2.70058
Chen, X., Yang, S. S., Sakamuru, S., Sukhawanit, C., Wood, S., Ooka, M., Huang, R., & Xia, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1788041
“…discovery efforts have been hampered by the pathway’s functional redundancy, complexity, and essential physiological roles, leading to off-target toxicities and the emergence of resistance (Kahn, 2014; Park and Kim, 2023; Nusse and Clevers, 2017; Zhong and Virshup, 2020; Hushmandi et al., 2025).”
Research Progress of Proteolysis‐Targeting Chimera Technology and Its Linkers in Cancer Therapy
Yang, J., & Zhang, X. (2026) · ChemMedChem · doi:10.1002/cmdc.70291
“…PROTAC technology has the following significant advantages: (1) PROTAC acts through “ event-driven ” and does not rely on continuous occupation of the active site of target proteins, so it can achieve efficient degradation at lower doses and reduce the exposure time of drugs in vivo [19, 20].”
Patel, G., Pathak, Y. V., & Prajapati, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36783-0.00004-6
Li, P., Li, J., Wang, Y., Han, X., Cao, Y., Jiang, M., Bao, Y., Wu, W. C., & Liu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14061382
“However, the complexity of Wnt signaling cascades poses significant challenges for drug development and clinical application [49].”
Modular plug-and-play crosslinking platform for precision-engineered hydrogels
Evans, A. D., Parvathaneni, R. P., Rahikainen, R., Varghese, O. P., Hytönen, V. P., & Oommen, O. P. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103457
Saegusa, M. (2026) · Pathology International · doi:10.1111/pin.70168
Korkmaz, I. F., Elgün, T., Aktas, Ç., Eslamkhah, S., Sevinç, S. K., & Yurttaş, A. G. (2026) · Pharmaceuticals · doi:10.3390/ph19091472
“The Wnt/ β -catenin pathway is frequently dysregulated in cancer and contributes to proliferation, epithelial–mesenchymal transition, stemness and apoptosis resistance [15,16], and its aberrant activation in pancreatic cancer has been linked to aggressive behaviour and therapeutic resistance [5,17].”
Investigating DIX-mediated interactions in Wnt signaling with AlphaFold2 and AlphaFold3
Lee, H. (2026) · Cell Signaling · doi:10.46439/signaling.4.107
More, R., Sanka, K., & Kuttiappan, A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.109004
Bhanja, P., Chugh, R. M., Rehman, S., Krepel, S. A., Mitra, A., Gupta-Saraf, P., Olea, X. D., Arora, T., Pathak, H. B., MD, M. A. K., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218879
Metadata
- Authors
- Park, W.-J., & Kim, M. J.
- Affiliations
- Gachon University (KR)
- Corresponding author
- Kim, Moon Jong
- ORCID
- Kim, Moon Jong
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-04-08
- Volume
- 12
- Issue
- 8
- Pages
- 1110
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC10136927
- OpenAlex
- W4363648015
- Cited by
- 57
- References
- 188
- Citations by year
- 2026: 18 · 2025: 13 · 2024: 20 · 2023: 6
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Gachon University (GCU-202110420001, NRF-2022R1F1A1074582)
- Korean government (MSIT) (GCU-202110420001, NRF-2022R1F1A1074582)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- Wnt signaling, undruggable targets, cancer therapy, Wnt inhibitors, PROTACs, molecular glues, antibody-drug conjugates, antisense oligonucleotides, clinical trials
- MeSH terms
- Cell Transformation, Neoplastic, Humans, Neoplasms, Stem Cells, Wnt Signaling Pathway, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.